Comparative Pharmacology
Head-to-head clinical analysis: ANECTINE versus MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANECTINE versus MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER.
ANECTINE vs MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker; mimics acetylcholine at nicotinic receptors at the neuromuscular junction, causing sustained depolarization and receptor desensitization.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine-mediated depolarization and muscle contraction.
1-1.5 mg/kg IV bolus for intubation; maintenance infusion: 2.5-4.3 mg/min IV; alternatively, 3-4 mg/kg IM for intubation.
Initial IV bolus of 0.15-0.2 mg/kg (following succinylcholine) or 0.25 mg/kg (without succinylcholine) over 30-60 seconds. Maintenance infusion: 8-10 mcg/kg/min for continuous neuromuscular blockade during anesthesia.
None Documented
None Documented
2-5 minutes (pseudocholinesterase hydrolysis); terminal half-life of succinylmonocholine ~30-60 minutes; clinical duration of apnea determined by rapid initial hydrolysis
Terminal elimination half-life is approximately 2-3 minutes (0.03-0.05 h) due to rapid hydrolysis by plasma esterases; clinical duration is short, with recovery of neuromuscular function beginning within 5-10 minutes after bolus dose.
Renal: 10-15% unchanged; hepatic: rapid hydrolysis by plasma pseudocholinesterase (butyrylcholinesterase) to succinylmonocholine and succinic acid; <2% biliary; <2% fecal
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of the dose; biliary/fecal elimination accounts for the remainder, primarily as metabolites via the liver.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker